Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;82(5):523-524.
doi: 10.1001/jamaneurol.2025.0337.

Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis

Liza M Y Gelissen  1 , Martijn T Wijburg  1 , Eva M M Strijbis  1 , Bob W van Oosten  1 , Brigit A de Jong  1 , Bernard M J Uitdehaag  1 , Theo Rispens  2   3 , Mariet C W Feltkamp  2   4 , Zoé L E van Kempen  1 , Joep Killestein  1
Affiliations

Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis

Liza M Y Gelissen et al. JAMA Neurol. .

Erratum in

  • Errors in the Results.
    [No authors listed] [No authors listed] JAMA Neurol. 2025 May 1;82(5):529. doi: 10.1001/jamaneurol.2025.1468. JAMA Neurol. 2025. PMID: 40354078 Free PMC article. No abstract available.
  • Erratum: Error in the Results.
    [No authors listed] [No authors listed] JAMA Neurol. 2025 Oct;82(10):1077. doi: 10.1001/jamaneurol.2025.3097. Epub 2025 Aug 18. JAMA Neurol. 2025. PMID: 40824646 Free PMC article.
No abstract available

Plain language summary

This cross-sectional study examines the increase in positive results for John Cunningham virus antibodies and higher risk for progressive multifocal leukoencephalopathy among patients with multiple sclerosis receiving natalizumab.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Prof Uitdehaag reported receiving trial funding from Immunic Therapeutics outside the submitted work. Dr Rispens reported receiving grants from Genmab and personal fees from Novartis outside the submitted work. Prof Killestein reported receiving grants from ZonMw/MS Research Foundation (DOT-MS trial), Treatmeds (Supernext trial), and ZonMw/Treatmeds (BLOOMS trial) and received consulting or speaker fees (all payments to institution) from F Hoffmann-La Roche Consultancy, Biogen, Merck, Novartis, Sanofi, Sandoz, and Immunic. No other disclosures were reported.

References

    1. Polman CH, O’Connor PW, Havrdova E, et al. ; AFFIRM Investigators . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910. doi: 10.1056/NEJMoa044397 - DOI - PubMed
    1. Lee P, Plavina T, Castro A, et al. A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol. 2013;57(2):141-146. doi: 10.1016/j.jcv.2013.02.002 - DOI - PubMed
    1. European Medicines Agency. Assessment report: Tyruko. International non-proprietary name: natalizumab. 2023. Accessed October 15, 2024. https://www.ema.europa.eu/en/documents/assessment-report/tyruko-epar-pub...
    1. Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16(11):925-933. doi: 10.1016/S1474-4422(17)30282-X - DOI - PubMed
    1. Adler F, Andersen M, Bartl T, et al. A new assay for detection of anti-JCV antibodies to support risk stratification and monitoring for progressive multifocal leukoencephalopathy in patients considering or in treatment with natalizumab. Poster presented at the European Committee for Treatment and Research in Multiple Sclerosis Congress; September 18, 2024; Copenhagen, Denmark. Accessed November 25, 2024. https://www.charcot-ms.org/files/ID-99-Maja-Natek.pdf

LinkOut - more resources